GSK
1,779.50 GBpChange from previous close: −0.86%Absolute change: −15.50 GBp
At a glance
- Revenue growth
- +4.11%
- 2025 vs 2024
- Net income growth
- +121.98%
- 2025 vs 2024
- Net margin
- 17.5%
- 2024: 8.2%
Financial data
Amounts in millions of GBP; per-share values in GBP; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2,690 | 1,141 | 2,278 | 2,222 | 2,096 | 1,145 | 2,329 | 2,154 | 1,113 | 958 | 3,196 | 2,212 |
| Depreciation and amortization | 223 | 463 | -626 | 738 | 619 | 823 | 201 | 951 | 639 | 549 | 420 | 579 |
| Capital expenditure | -328 | -221 | -573 | -311 | -256 | -208 | -544 | -305 | -302 | -248 | -486 | -299 |
| Investing cash flow | -789 | -1,466 | -933 | -1,531 | -625 | -1,144 | -1,119 | -731 | 770 | -149 | 268 | -491 |
| Financing cash flow | -2,149 | 272 | -856 | -1,315 | -2,372 | 858 | -842 | -1,240 | -1,584 | -1,060 | -3,592 | -1,762 |
| Dividends paid | -727 | -643 | -646 | -650 | -656 | -612 | -612 | -612 | -652 | -568 | -568 | -567 |
| Share repurchases | -308 | -326 | -252 | -317 | -561 | -247 | — | — | — | — | — | — |
| Debt issued | 273 | 1,202 | 552 | -80.0 | 645 | 2,077 | 1,341 | — | — | — | -1,409 | -615 |
| Debt repaid | -958 | -73.0 | -79.0 | -62.0 | -1,572 | -216 | -1,153 | -604 | -596 | -380 | -1,410 | -483 |
| Effect of exchange rates | -7.0 | 2.0 | -41.0 | 59.0 | -26.0 | -11.0 | 7.0 | -34.0 | -8.0 | -19.0 | -34.0 | 23.0 |
| Net change in cash | -212 | -51.0 | 448 | -565 | -927 | 848 | 375 | 149 | 291 | -270 | -162 | -18.0 |
| Free cash flow | 2,362 | 920 | 1,705 | 1,911 | 1,840 | 937 | 1,785 | 1,849 | 811 | 710 | 2,710 | 1,913 |
| Levered free cash flow | 1,099 | 485 | 223 | 1,385 | 367 | 750 | 1,937 | 1,887 | 510 | 579 | 3,032 | 1,345 |